Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DelveInsight | PRODUCT CODE: 1179487

Cover Image

PUBLISHER: DelveInsight | PRODUCT CODE: 1179487

Cancer Pain - Epidemiology Forecast - 2032

PUBLISHED:
PAGES: 79 Pages
DELIVERY TIME: 1-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 3950
PDF (Site License)
USD 7900
PDF (Global License)
USD 11850

Add to Cart

DelveInsight's 'Cancer Pain Overview - Epidemiology Forecast-2032' report delivers an in-depth understanding of the cancer pain historical and forecasted epidemiology as well as the cancer pain epidemiology trends in the United States, EU4 (Germany, France, Italy, Spain) and the UK, and Japan.

Cancer Pain Understanding

Cancer Pain Overview

The International Association for the study of pain defines pain as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage." Worldwide, many people are affected by cancer, and the prevalence is rising. Pain is the most typical symptom of cancer at diagnosis and rises in prevalence throughout and beyond cancer treatment and continues to be a major source of suffering in advanced cancer with adverse effects on patients' life quality and caregiver distress. Cancer pain is a complex biologic phenomenon that is poorly understood or classified. No specific and widely acceptable taxonomy of cancer pain exists. In any given patient, different mechanisms can be responsible for the pain.

Continued in the report…

Etiology and Types of Cancer Pain

Generally, in cancer, the pain is caused by the primary tumor, metastatic disease, or cancer-related treatments; however, a primary cause of the pain cannot always be identified. Most cancer pain is caused by the tumor pressing on bones, nerves, or other organs in the body. Classifications based on the pain duration are acute pain, chronic pain, breakthrough pain, and refractory pain.

Acute pain is due to damage caused by an injury and usually lasts <3-6 months. For example, having an operation can cause acute pain. The pain goes when the wound heals; in the meantime, painkillers will usually keep it under control.

Chronic pain lasts >3-6 months and is persistent due to nerve changes. Nerve changes may be due to cancer pressing on nerves or chemicals produced by a tumor. Nerve changes due to cancer treatment can also cause it. Chronic pain continues long after the injury or treatment is over, can range from mild to severe, and can always be there. Sometimes pain can come on quickly, for example, when changing a dressing or moving around; this type is incident pain.

Continued in the report…

Cancer Pain Epidemiology Perspective by DelveInsight

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Cases of Cancer Pain, Etiology-specific Cases of Cancer Pain, Incident Cases of Chemotherapy-Induced Peripheral Neuropathy, Severity-specific Cases of Cancer Pain, Pathophysiology-specific Cases of Cancer Pain, Temporal Variation-specific Cases of Cancer Pain, Incident Cases of Breakthrough Cancer Pain (BTcP) covering the United States, the EU4 (Germany, France, Italy, Spain), UK and Japan from 2019 to 2032.

Cancer Pain Detailed Epidemiology Segmentation

  • In 2021, the total incident cases of cancer pain in the US were ~2,321,000 cases, which are anticipated to increase in 2032.
  • EU4 and the UK, in 2021, accounted for ~2,278,000 cases of cancer pain, which are anticipated to increase by the year 2032.
  • Among the EU4 countries, the highest number of cases of cancer pain were found in Germany, i.e., ~634,000 cases in the year 2021, which are estimated to increase by the year 2032.
  • In 2021, the incident cases of breakthrough cancer pain were ~379,000 in France. These cases are expected to increase during the forecast period.

Scope of the Report:

  • The report covers a descriptive overview of cancer pain, explaining its procedure, types and indications.
  • The report provides insight into 7MM historical and forecasted patient pool covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom and Japan.
  • The report assesses the cancer pain risk and burden.
  • The report provides the segmentation of the epidemiology for 7MM by segmented by 'Total Cases of Cancer Pain, Etiology-specific Cases of Cancer Pain, Incident Cases of Chemotherapy-Induced Peripheral Neuropathy, Severity-specific Cases of Cancer Pain, Pathophysiology-specific Cases of Cancer Pain, Temporal Variation-specific Cases of Cancer Pain, Incident Cases of Breakthrough Cancer Pain (BTcP)'.

Report Highlights:

  • 11-Year Forecast of Cancer Pain
  • 7MM Coverage
  • Total Cases of Cancer Pain
  • Etiology-specific Cases of Cancer Pain
  • Incident Cases of Chemotherapy-Induced Peripheral Neuropathy
  • Severity-specific Cases of Cancer Pain
  • Pathophysiology-specific Cases of Cancer Pain
  • Temporal Variation-specific Cases of Cancer Pain
  • Incident Cases of Breakthrough Cancer Pain (BTcP)

Key Questions Answered

  • What are the risk, burdens, and unmet needs of cancer pain?
  • What is the historical cancer pain patient pool in the United States, EU4 (Germany, France, Italy, Spain), UK and Japan?
  • What would be the forecasted patient pool of cancer pain at the 7MM Coverage level?
  • What will be the growth opportunities across the 7MM coverage with respect to the patient population pertaining to cancer pain?
  • Out of the countries mentioned above, which country would have the highest cases of cancer pain during the forecast period (2022-2032)?
  • At what CAGR the population is expected to grow across the 7MM Coverage during the forecast period (2022-2032)?

Reasons to buy:

The cancer pain report will allow the user to -

  • Develop business strategies by understanding the trends, shaping and driving the 7MM cancer pain epidemiology.
  • The cancer pain epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The cancer pain epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Geographies Covered

  • The United States
  • EU4 (Germany, France, Italy, Spain) and the UK
  • Japan

Study Period: 2019-2032

Product Code: DIEI1446

Table of Contents

1. Key Insights

2. Report Introduction

3. Cancer Pain Market Overview at a Glance

  • 3.1. Market Share (%) Distribution of Cancer Pain by Therapies in 2019
  • 3.2. Market Share (%) Distribution of Cancer Pain by Therapies in 2032

4. Executive Summary of Cancer Pain

5. Key events

6. Disease Background and Overview

  • 6.1. Introduction
  • 6.2. Etiology and Types
  • 6.3. Cancer Pain Classification Systems
    • 6.3.1. International Association for the Study of Pain (IASP) Taxonomy
    • 6.3.2. ICD-11
    • 6.3.3. Edmonton Classification System for Cancer Pain (ECS-CP)
  • 6.4. Cancer Pain Pathophysiology
  • 6.5. Cancer Pain Syndromes
  • 6.6. Clinical Presentation and Assessment of Pain

7. Treatment and Management

  • 7.1. NCCN Guidelines
  • 7.2. ESMO Clinical Practice Guidelines (2018)
  • 7.3. Spanish Guidelines
  • 7.4. Canadian Recommendations for the Management of Breakthrough Cancer Pain (BTCP)
  • 7.5. Multimodal Personalized Management of Cancer Pain

8. Methodology

9. Epidemiology and Patient Population

  • 9.1. Key Findings
  • 9.2. Assumptions and Rationale
  • 9.3. Epidemiology Scenario: 7MM
    • 9.3.1. Total cases of cancer pain in the 7MM
  • 9.4. The United States
    • 9.4.1. Total cases of cancer pain in the United States
    • 9.4.2. Etiology-specific cases of cancer pain in the United States
    • 9.4.3. Incidence of chemotherapy-induced peripheral neuropathy in the United States
    • 9.4.4. Severity-specific cases of cancer pain in the United States
    • 9.4.5. Pathophysiology-specific cases of cancer pain in the United States
    • 9.4.6. Temporal variation-specific cases of cancer pain in the United States
    • 9.4.7. Incidence of breakthrough cancer pain (BTcP) in the United States
  • 9.5. EU4 and the UK
    • 9.5.1. Total cases of cancer pain in EU4 and the UK
    • 9.5.2. Etiology-specific cases of cancer pain in EU4 and the UK
    • 9.5.3. Incidence of chemotherapy-induced peripheral neuropathy in EU4 and the UK
    • 9.5.4. Severity-specific cases of cancer pain in EU4 and the UK
    • 9.5.5. Pathophysiology-specific cases of cancer pain in EU4 and the UK
    • 9.5.6. Temporal variation-specific cases of cancer pain in EU4 and the UK
    • 9.5.7. Incidence of breakthrough cancer pain (BTcP) in EU4 and the UK
  • 9.6. Japan
    • 9.6.1. Total cases of cancer pain in Japan
    • 9.6.2. Etiology-specific cases of cancer pain in Japan
    • 9.6.3. Incidence of chemotherapy-induced peripheral neuropathy in Japan
    • 9.6.4. Severity-specific cases of cancer pain in Japan
    • 9.6.5. Pathophysiology-specific cases of cancer pain in Japan
    • 9.6.6. Temporal variation-specific cases of cancer pain in Japan
    • 9.6.7. Incidence of breakthrough cancer pain (BTcP) in Japan

10. Unmet Needs

11. SWOT Analysis

12. Appendix

  • 12.1. Report Methodology
  • 12.2. Bibliography

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

Product Code: DIEI1446

List of Tables

  • Table 1: Summary of Cancer Pain and Epidemiology (2019-2032)
  • Table 2: Key Events
  • Table 3: Acute Pain Syndromes Associated With Antineoplastic Treatments
  • Table 4: Chronic Pain Syndromes Associated With Cancer Treatment
  • Table 5: Levels of evidence and grades of recommendation
  • Table 6: Total Cases of Cancer pain in the 7MM in '000s (2019-2032)
  • Table 7: Total Cases of Cancer Pain in the US in '000s (2019-2032)
  • Table 8: Etiology-specific Cases of Cancer Pain in the United States in '000s (2019-2032)
  • Table 9: Incidence of Chemotherapy-Induced Peripheral Neuropathy in the United States in '000s (2019-2032)
  • Table 10: Severity-specific Cases of Cancer Pain in the United States in '000s (2019-2032)
  • Table 11: Pathophysiology-specific Cases of Cancer Pain in the United States in '000s (2019-2032)
  • Table 12: Temporal Variation-specific Cases of Cancer Pain in the United States in '000s (2019-2032)
  • Table 13: Incidence of Breakthrough Cancer Pain (BTcP) in the United States in '000s (2019-2032)
  • Table 14: Total Cases of Cancer Pain in EU4 and the UK in '000s (2019-2032)
  • Table 15: Etiology-specific Cases of Cancer Pain in EU4 and the UK in '000s (2019-2032)
  • Table 16: Incidence of Chemotherapy-Induced Peripheral Neuropathy in EU4 and the UK in '000s (2019-2032)
  • Table 17: Severity-specific Cases of Cancer Pain in EU4 and the UK in '000s (2019-2032)
  • Table 18: Pathophysiology-specific Cases of Cancer Pain in EU4 and the UK in '000s (2019-2032)
  • Table 19: Temporal Variation-specific Cases of Cancer Pain in EU4 and the UK (2019-2032)
  • Table 20: Incidence of Breakthrough Cancer Pain (BTcP) in EU4 and the UK (2019-2032)
  • Table 21: Total Cases of Cancer Pain in Japan in '000s (2019-2032)
  • Table 22: Etiology-specific Cases of Cancer Pain in Japan in '000s (2019-2032)
  • Table 23: Incidence of Chemotherapy Induced Peripheral Neuropathy in Japan in '000s (2019-2032)
  • Table 24: Severity-specific Cases of Cancer Pain in Japan in '000s (2019-2032)
  • Table 25: Pathophysiology-specific Cases of Cancer Pain in Japan in '000s (2019-2032)
  • Table 26: Temporal Variation-specific Cases of Cancer Pain in Japan in '000s (2019-2032)
  • Table 27: Incidence of Breakthrough Cancer Pain (BTcP) in Japan in '000s (2019-2032)

List of Figures

  • Figure 1: Cancer Pain Etiologies
  • Figure 2: Modified WHO Analgesic Ladder
  • Figure 3: Screening and Assessment for Patients With Cancer Pain
  • Figure 4: Screening and Assessment for Patients With Cancer Pain
  • Figure 5: Algorithm for Assessment of Breakthrough Cancer Pain
  • Figure 6: Multimodal Cancer Patient Management
  • Figure 7: The Analgesic Trolley Model for Pain Management
  • Figure 8: Total Cases of Cancer Pain in the 7MM in '000s (2019-2032)
  • Figure 9: Total Cases of Cancer Pain in the US in '000s (2019-2032)
  • Figure 10: Etiology-specific Cases of Cancer Pain in the US '000s (2019-2032)
  • Figure 11: Incidence of Chemotherapy-Induced Peripheral Neuropathy in the United States in '000s (2019-2032)
  • Figure 12: Severity-specific Cases of Cancer Pain in the United States in '000s (2019-2032)
  • Figure 13: Pathophysiology-specific Cases of Cancer Pain in the United States in '000s (2019-2032)
  • Figure 14: Temporal Variation-specific Cases of Cancer Pain in the United States in '000s (2019-2032)
  • Figure 15: Incidence of Breakthrough Cancer Pain (BTcP) in the United States in '000s (2019-2032)
  • Figure 16: Total Cases of Cancer Pain in EU4 and the UK in '000s (2019-2032)
  • Figure 17: Etiology-specific Cases of Cancer Pain in EU4 and the UK in '000s (2019-2032)
  • Figure 18: Incidence of Chemotherapy Induced Peripheral Neuropathy in EU4 and the UK in '000s (2019-2032)
  • Figure 19: Severity-specific Cases of Cancer Pain in EU4 and the UK in '000s (2019-2032)
  • Figure 20: Pathophysiology-specific Cases of Cancer Pain in EU4 and the UK in '000s (2019-2032)
  • Figure 21: Temporal Variation-specific Cases of Cancer Pain in EU4 and the UK (2019-2032)
  • Figure 22: Incidence of Breakthrough Cancer Pain (BTcP) in EU4 and the UK (2019-2032)
  • Figure 23: Total Cases of Cancer Pain in Japan in '000s (2019-2032)
  • Figure 24: Etiology-specific Cases of Cancer Pain in Japan in '000s (2019-2032)
  • Figure 25: Incidence of Chemotherapy Induced Peripheral Neuropathy in Japan in '000s (2019-2032)
  • Figure 26:Severity-specific Cases of Cancer Pain in Japan in '000s (2019-2032)
  • Figure 27: Pathophysiology-specific Cases of Cancer Pain in Japan in '000s (2019-2032)
  • Figure 28: Temporal Variation-specific Cases of Cancer Pain in Japan in '000s (2019-2032)
  • Figure 29: Incidence of Breakthrough Cancer Pain (BTcP) in Japan in '000s (2019-2032)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!